Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

Please provide your email address to receive an email when new articles are posted on . Four biosimilars for Stelara have launched in the United States this year following legal settlements with the ...

MedImpact Holdings is planning to offer an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than Stelara. The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals ...

Leading up to the entry of the first Stelara biosimilars in the U.S. at the start of 2025, executives at Johnson & Johnson remained steadfast in their belief that the company could maintain revenue ...

Credit: Celltrion Steqeyma, formerly known as CT-P43, is a human interleukin-12 and -23 antagonist. According to Celltrion, Steqeyma is expected to be available in February 2025. The Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Steqeyma as the seventh Stelara biosimilar with an expected launch date of February 2025.

Alternative pharmacy benefit manager Serve You Rx is seeking to generate additional savings for its clients by adding two biosimilars for the popular drug Stelara to its formulary. The PBM will add ...

Serve You Rx, a pharmacy benefit manager, has added two recently approved biosimilars to Stelara to its formulary, the company announced Thursday. Milwaukee, Wisconsin-based Serve You Rx is an ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the steady ...

Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...